Possible Role of Roflumilast in Diabetic Nephropathy
Status:
Not yet recruiting
Trial end date:
2021-07-10
Target enrollment:
Participant gender:
Summary
adding roflumilast to the standard therapy for diabetic nephropathy and studying the
progression of many outcomes including urinary albumin to creatinine ratio, estimated GFR,
biomarkers of diabetic nephropathy